Physician profile
Patrick Crandell
NPI 1508298498
$7,131.56
in general payments reported to CMS, 2019-2025
23 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $1,222 · 2023: $1,632 · 2024: $1,420 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,879 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,879.38 |
| Education | $117.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.40 | 2021-2025 | |
| Janssen Biotech, INC. | $826.10 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $652.61 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $471.90 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $465.21 | 2021-2025 | Dupixent |
| Amgen INC. | $454.14 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $440.25 | 2021-2025 | Bimzelx |
| Pfizer INC. | $421.29 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $385.17 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Lilly USA, LLC | $382.42 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $315.76 | 2022-2024 | Vtama |
| Genzyme Corporation | $297.21 | 2021-2025 | |
| Incyte Corporation | $206.82 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $199.81 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $166.12 | 2021-2025 | Adbry |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $118.56 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $46.18 | 2021 | |
| Organogenesis INC. | $33.18 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.66 | 2022-2023 | Spevigo |
| Blueprint Medicines Corporation | $29.47 | 2023 | |
| Verrica Pharmaceuticals INC. | $17.16 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $15.90 | 2024 | Xtrac |
| Organon LLC | $15.24 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Crandell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.